Biothera Pharmaceuticals is partnering with leading institutions in cancer immunotherapy to advance Imprime PGG for next generation immunotherapy.

Merck, a global health care leader for 125 years, is translating breakthrough science into innovative oncology medicines to help people with cancer worldwide.  

Biothera and Merck have multiple clinical trial collaborations to evaluate the safety and efficacy of Imprime PGG and KEYTRUDA® (Merck’s anti-PD-1 checkpoint inhibitor) in patients with advanced melanoma and metastatic triple negative breast cancer.


For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. 

Biothera and Genentech, Inc., a member of the Roche Group, have a clinical trial collaboration to assess the safety and efficacy of Imprime PGG in combination with Genentech’s TECENTRIQ®, an anti-PD-L1 antibody, and AVASTIN®, an anti-VEGF antibody, to treat patients with metastatic colorectal cancer.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. 

Biothera and AstraZeneca have announced a clinical collaboration to evaluate Imprime PGG and IMFINZI® (durvalumab) in certain patients with head and neck cancer.  The planned Phase 2 neoadjuvant study will assess whether this therapeutic combination can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.

The Big Ten cancer centers are transforming cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities.

The Big Ten Cancer Research Consortium is conducting a Phase 1b/2 study in second line non-small cell lung cancer with KEYTRUDA and Imprime PGG, under separate collaboration agreements with Merck and Biothera. 

Dana-Farber Cancer Institute is committed to providing expert, compassionate care to children and adults with cancer, while advancing the understanding, treatment, cure, and prevention of cancer and related diseases.

Dana-Farber Cancer Institute has completed a Phase 2 clinical trial of Rituxan® (rituximab) and Imprime PGG in relapsed/refractory indolent B cell non-Hodgkin’s lymphoma.

The University of Pennsylvania’s Abramson Cancer Center is a world leader in cancer research, patient care and education. Its preeminent position is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 47 such centers in the United States.

The Abramson Cancer Center has completed a preclinical study evaluating Imprime PGG in combination with a CD40 agonist antibody in a preclinical pancreatic cancer model.  Data were presented at the American Association for Cancer Research annual meeting in 2018.

To accelerate the understanding of Imprime PGG’s therapeutic mechanism of action and activity, Biothera Pharmaceuticals has also partnered extensively with some of the world’s most notable academic institutions, including Johns Hopkins University, Harvard University, Dartmouth, and the Wistar Institute.

Interested in partnering with Biothera Pharmaceuticals?  
In addition to building a dedicated team of immunologists, biologists and chemists, Biothera works closely with researchers at leading universities, government institutions, and research centers around the world. If you, or your institution, are seeking support from Biothera to conduct an Investigator-Initiated Study (IIS) with Imprime PGG, please contact us at